公开(公告)号：US10899796B2

公开(公告)日：2021-01-26

申请号：US15774451

申请日：2016-11-09

Applicant: Tufts Medical Center ,  Trustees of Tufts College

Inventor： Alan S. Kopin ,  Krishna Kumar ,  Jamie Raudensky Doyle

IPC: C07K7/08 ,  C07K14/665 ,  A61K38/10 ,  A61K38/33 ,  C07K14/68 ,  C07K19/00 ,  C07K7/00 ,  A61K47/54 ,  A61K47/65 ,  A61K47/60 ,  A61P25/00 ,  A61K38/34 ,  C07K7/64

Abstract: The present disclosure relates to, among other things, compounds and methods for treating neuropathic pain, ocular pain, ocular inflammation, and/or dry eye and methods of detecting mutations in specific G-protein coupled receptors, such as missense mutations, and determining the extent to which these mutations alter the pharmacological response of the G-protein coupled receptor.

公开(公告)号：US10195219B2

公开(公告)日：2019-02-05

申请号：US14351766

申请日：2014-04-11

Applicant: Rebecca Lambert Bent

Inventor： Rebecca Lambert Bent

IPC: A61K31/664 ,  A61K31/12 ,  A61K31/485 ,  A61K31/155 ,  A61K31/385 ,  A61K31/352 ,  A61K45/06 ,  A61K31/198 ,  A61K31/4045 ,  A61K31/575 ,  A61K31/675 ,  A61K31/7048 ,  A61K38/33 ,  A61K38/08

Abstract: The present invention is directed to compositions and methods for the treatment of cancers, particularly cancers of epithelial origin. Therapy with a plurality of nutraceutical, non-chemotherapeutic and chemotherapeutic agents, that together target a plurality of cancer-supportive processes in a patient are disclosed. Among other things, the present invention encompasses the insight that redundant targeting of multiple such pathways provides effective treatment of various cancer, including late-stage cancers, metastasized cancers, and/or cancers that have failed treatment with traditional chemotherapy and/or other therapeutic modalities.

公开(公告)号：US10086084B2

公开(公告)日：2018-10-02

申请号：US15453686

申请日：2017-03-08

Applicant: SERINA THERAPEUTICS, INC.

Inventor： J Milton Harris ,  Michael David Bentley ,  Kunsang Yoon ,  Zhihao Fang ,  Francesco Maria Veronese ,  Tacey Viegas

IPC: A61K38/18 ,  A61K47/48 ,  A61K31/727 ,  A61K38/33 ,  A61K38/47 ,  A61K31/728 ,  A61K38/19 ,  A61K38/27 ,  A61K38/42 ,  C08G69/48

Abstract: The present disclosure provides POZ derivatives having a range of active functional groups allowing conjugation of POZ derivatives to a variety of target molecules under a wide range of reaction conditions to produce a hydrolytically stable target molecule-POZ conjugate. Furthermore, the present disclosure provides novel methods of synthesis for the disclosed POZ derivatives and hydrolytically stable target molecule-POZ conjugates created using the disclosed terminally activated monofunctional POZ derivatives. In one embodiment, the POZ derivative is a terminally activated monofunctional POZ derivative.

公开(公告)号：US09486493B2

公开(公告)日：2016-11-08

申请号：US12449944

申请日：2008-03-07

Applicant: Andrzej W. Lipkowski ,  Daniel Carr ,  Aleksandra Misicka-Kesik ,  Piotr Kosson ,  Anna Klinowiecka

Inventor： Andrzej W. Lipkowski ,  Daniel Carr ,  Aleksandra Misicka-Kesik ,  Piotr Kosson ,  Anna Klinowiecka

IPC: A61K38/08 ,  A61P25/00 ,  A61K38/33

CPC classification number: A61K38/08 ,  A61K38/33

Abstract: Inflammation caused by disease states such as rheumatism, gout, neurodegeneration and tumours result in the increased effectiveness of the opioid peptide biphalin or its analogues, due likely to the increased permeability of the “blood-brain barrier”, due to which it becomes possible to use the opioid peptide to produce a new analgesic for use during inflammation caused by rheumatism, gout, neurodegeneration, post-surgical or post-accidental trauma or tumours.

Abstract translation: 由风湿病，痛风，神经变性和肿瘤等疾病引起的炎症导致阿片样物质白蛋白或其类似物的有效性增加，这可能是由于“血脑屏障”的渗透性增加，由此可能导致 使用阿片类肽产生一种新的镇痛药，用于炎症，痛风，神经变性，手术后或意外创伤或肿瘤引起的炎症。

公开(公告)号：US09296707B2

公开(公告)日：2016-03-29

申请号：US14503758

申请日：2014-10-01

Applicant: VERSI GROUP, LLC

Inventor： Kwen-Jen Chang ,  Klim King ,  Kestutis P. Biciunas ,  Robert W. McNutt ,  William Pendergast ,  Shyi-Tai Jan

IPC: C07D241/04 ,  A61K31/00 ,  A61K31/445 ,  A61K31/495 ,  A61K31/519 ,  A61K38/33

CPC classification number: C07D241/04 ,  A61K31/00 ,  A61K31/445 ,  A61K31/495 ,  A61K31/519 ,  A61K38/33 ,  A61K2300/00

Abstract: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.

公开(公告)号：US20150045719A1

公开(公告)日：2015-02-12

申请号：US14385416

申请日：2013-03-15

Applicant: GALDERMA RESEARCH & DEVELOPMENT

Inventor： Carole Chomat ,  Philippe Martel ,  Johannes Voegel

IPC: A61N5/06 ,  A61K38/35 ,  A61K31/4196 ,  A61K31/454 ,  A61K31/435 ,  A61K31/4178 ,  A61K38/34 ,  A61K38/33

CPC classification number: A61N5/062 ,  A61K31/397 ,  A61K31/40 ,  A61K31/4178 ,  A61K31/4196 ,  A61K31/435 ,  A61K31/445 ,  A61K31/454 ,  A61K38/33 ,  A61K38/34 ,  A61K38/35 ,  A61K45/06 ,  A61N5/0614 ,  A61N2005/0661 ,  F04C2270/041 ,  A61K2300/00 ,  A61K31/00

Abstract: A system comprising a combination of at least one MC1R receptor agonist and a source of NB-UVB, wherein said system is adapted for simultaneous or sequential use of said MC1R receptor agonist and said NB-UVB in amounts effective for the treatment and/or prevention of dermatological conditions linked to a hypopigmentation.

Abstract translation: 包含至少一种MC1R受体激动剂和NB-UVB源的组合的系统，其中所述系统适于同时或顺序地使用所述MC1R受体激动剂和所述NB-UVB，其量对于治疗和/或预防有效 与色素沉着相关的皮肤病学条件。

公开(公告)号：US08865721B2

公开(公告)日：2014-10-21

申请号：US14042893

申请日：2013-10-01

Applicant: Versi Group, LLC

Inventor： Kwen-Jen Chang ,  Klim King ,  Kestutis P. Biciunas ,  Robert W. McNutt ,  William Pendergast ,  Shyi-Tan Jan

IPC: A61K31/497 ,  A61K31/519 ,  A61K31/00 ,  A61K31/445 ,  A61K38/33 ,  C07D241/04 ,  A61K31/495

CPC classification number: C07D241/04 ,  A61K31/00 ,  A61K31/445 ,  A61K31/495 ,  A61K31/519 ,  A61K38/33 ,  A61K2300/00

Abstract: Compositions and methods for treatment of sexual dysfunctions by administering to a subject a pharmaceutical composition comprising a delta opioid receptor agonist in an amount effective to delay the onset of ejaculation in the subject during sexual stimulation.

Abstract translation: 用于治疗性功能障碍的组合物和方法，其通过向受试者施用包含δ阿片受体激动剂的药物组合物，所述药物组合物有效地延迟性刺激期间受试者的射精发作。

公开(公告)号：US20140127303A1

公开(公告)日：2014-05-08

申请号：US14126365

申请日：2012-06-13

Applicant: Joël Richard ,  Faïza Laredj ,  Maire-Madeleine Baronnet ,  Didier Nourrisson ,  Jeremiah Harnett ,  Béatrice Hacher ,  Nathalie Mondoly ,  Laurent Bertocchi

Inventor： Joël Richard ,  Faïza Laredj ,  Maire-Madeleine Baronnet ,  Didier Nourrisson ,  Jeremiah Harnett ,  Béatrice Hacher ,  Nathalie Mondoly ,  Laurent Bertocchi

IPC: A61K9/16 ,  A61K9/00 ,  A61K38/33

CPC classification number: A61K9/1652 ,  A61K9/0019 ,  A61K38/33

Abstract: The present invention relates to a sustained-release drug composition consisting essentially of microparticles of a peptide as the active substance and a biocompatible water-soluble polymer, in particular peptide as meianocortin receptor ligand. The present invention relates also to an injection formulation comprising the sustained-release drug composition suspended in an injection medium.

Abstract translation: 本发明涉及基本上由作为活性物质的肽的微粒和生物相容性水溶性聚合物，特别是作为肌钙蛋白受体配体的肽组成的缓释药物组合物。 本发明还涉及包含悬浮在注射培养基中的缓释药物组合物的注射制剂。

公开(公告)号：US20130344102A1

公开(公告)日：2013-12-26

申请号：US13836547

申请日：2013-03-15

Applicant: AIMSCO LIMITED

Inventor： David John Shotton ,  Syed Ebadat Haq ,  Deirdre Patricia McIntosh

IPC: A61K38/22 ,  A61K45/06 ,  A61K38/34 ,  A61K38/01 ,  A61K38/33

CPC classification number: A61K38/2228 ,  A61K35/16 ,  A61K38/017 ,  A61K38/22 ,  A61K38/33 ,  A61K38/34 ,  A61K38/57 ,  A61K45/06 ,  A61K47/42 ,  A61K2300/00

Abstract: The present invention relates to a CRH formulation having improved stability/efficacy. The improved CRH formulation is particularly suitable for treatment of various disorders. The invention also relates to a method of producing the CRH formulation, and to methods of treatment using said CRH formulation.

Abstract translation: 本发明涉及具有改善的稳定性/功效的CRH制剂。 改进的CRH制剂特别适用于治疗各种疾病。 本发明还涉及生产CRH制剂的方法以及使用所述CRH制剂的治疗方法。

公开(公告)号：US07456146B2

公开(公告)日：2008-11-25

申请号：US09938623

申请日：2001-08-27

Applicant: Xianxhang Yu ,  Thomas E. Wagner

Inventor： Xianxhang Yu ,  Thomas E. Wagner

IPC: A61K38/16 ,  A61K38/33 ,  A61K45/00 ,  C07K14/195 ,  C07K14/435

CPC classification number: C07K16/18 ,  A61K47/65 ,  Y10S530/82 ,  Y10S530/822 ,  Y10S530/825

Abstract: A cytotoxin can be rendered non-toxic by charge neutralizing the amino acids salient to pore assembly and/or sterically inhibiting formation of the peptide's active conformation. In the presence of specific proteases, the inactive peptide or procytotoxin can be activated to assemble into its lytic conformation and selectively destroy a target cell.

Abstract translation: 细胞毒素可以通过电荷中和纳米孔组装氨基酸和/或空间抑制肽的活性构象的形成而变得无毒。 在特定蛋白酶的存在下，可以活化无活性肽或原细胞毒素以组装成其裂解构象并选择性地破坏靶细胞。